Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Vinay Prasad named chief medical and scientific officer at FDA
Cancer Policy

Vinay Prasad named chief medical and scientific officer at FDA

June 20, 2025
Vol.51 No.24
By Claire Marie Porter
Cancer Policy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

June 20, 2025
Vol.51 No.24
By Claire Marie Porter
Clinical Roundup

Talvey + Tecvayli show deep and durable responses in heavily pretreated MM patients with extramedullary disease

June 20, 2025
Vol.51 No.24
Drugs & Targets

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

June 20, 2025
Vol.51 No.24
Drugs & Targets

FDA approves tafasitamab-cxix for r/r follicular lymphoma

June 20, 2025
Vol.51 No.24
Cancer Policy

Kennedy: “We’re going to end the war at FDA against alternative medicine”

June 13, 2025
Vol.51 No.23
By Jacquelyn Cobb
Drugs & Targets

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

June 13, 2025
Vol.51 No.23
FDA booth stood empty at 2025 ASCO annual meeting
Cancer Policy

FDA booth stood empty at 2025 ASCO annual meeting

June 06, 2025
Vol.51 No.22
By Jacquelyn Cobb
Makary: Level of evidence is an artificial and dogmatic construct
Cancer Policy

Makary: Level of evidence is an artificial and dogmatic construct

June 06, 2025
Vol.51 No.22
By Jacquelyn Cobb
Cancer Policy

FDA rolls out agency-wide AI tool

June 06, 2025
Vol.51 No.22
By Jacquelyn Cobb

Posts navigation

Previous1…161718…59Next

Trending Stories

  • “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
    In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process
  • Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
  • FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
    “Patients are owed another review.”
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
  • Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account